No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
Abp 959 |
- |
- |
- |
- |
[1] 62 |
2 |
Abp 959 - biosimilar to eculizumab |
Eculizumab |
D03940 |
[1] C5 |
[7] Complement and coagulation cascades, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Pertussis, Prion diseases, Staphylococcus aureus infection, Systemic lupus erythematosus |
[1] 62 |
3 |
Ach-0144471 |
- |
- |
- |
- |
[3] 62, 222, 223 |
4 |
Aln-62643 |
- |
- |
- |
- |
[1] 62 |
5 |
Aln-cc5 |
- |
- |
- |
- |
[2] 62, 109 |
6 |
Alxn1102 |
- |
- |
- |
- |
[1] 62 |
7 |
Alxn1103 |
- |
- |
- |
- |
[1] 62 |
8 |
Alxn1210 |
- |
- |
- |
- |
[2] 62, 109 |
9 |
Anti-c5 antibody |
- |
- |
- |
- |
[4] 11, 14, 62, 109 |
10 |
Anti-thymocyte globulin |
- |
- |
- |
- |
[18] 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285 |
11 |
Apl-2 |
- |
- |
- |
- |
[5] 61, 62, 66, 222, 223 |
12 |
Bcd-148 |
- |
- |
- |
- |
[1] 62 |
13 |
Bryostatin 1 |
Bryostatin 1 |
- |
- |
- |
[1] 62 |
14 |
C5 inh mab, sky59, ro/ch7092230 |
- |
- |
- |
- |
[1] 62 |
15 |
Campath, chemo and/or tbi allo sct |
- |
- |
- |
- |
[3] 60, 62, 283 |
16 |
Coversin |
Nomacopan |
D11473 |
[1] C5 |
[7] Complement and coagulation cascades, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Pertussis, Prion diseases, Staphylococcus aureus infection, Systemic lupus erythematosus |
[2] 62, 109 |
17 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[43] 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
18 |
Cyclosporin |
Ciclosporin |
D00184 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[16] 14, 38, 39, 49, 53, 56, 60, 62, 63, 97, 113, 164, 222, 223, 274, 326 |
19 |
Cyclosporin a |
Ciclosporin |
D00184 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[11] 14, 38, 39, 49, 53, 56, 60, 62, 63, 113, 164 |
20 |
Cyclosporin a+glucocorticoids |
Ciclosporin |
D00184 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[2] 60, 62 |
21 |
Cyclosporine |
Ciclosporin |
D00184 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[33] 11, 14, 19, 20, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
22 |
Cytoreductive regimen followed by a cd34+e- selected allogeneic stem cell transplant |
- |
- |
- |
- |
[1] 62 |
23 |
Dextran |
Dextran |
D00060 |
- |
- |
[5] 2, 62, 79, 96, 97 |
24 |
Eculizumab |
Eculizumab |
D03940 |
[1] C5 |
[7] Complement and coagulation cascades, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Pertussis, Prion diseases, Staphylococcus aureus infection, Systemic lupus erythematosus |
[7] 11, 13, 14, 62, 109, 222, 223 |
25 |
Fc- and cdr-modified humanised monoclonal antibody against c5 |
- |
- |
- |
- |
[2] 62, 109 |
26 |
Filgrastim |
Filgrastim |
D03235 |
[1] CSF3R |
[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
[25] 2, 6, 13, 25, 26, 28, 34, 35, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 283, 284, 285, 331 |
27 |
Fludarabine |
Fludarabine |
D01907, D07966 |
[1] RRM1 |
[5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
[17] 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 326 |
28 |
Fludarabine phosphate |
Fludarabine |
D01907, D07966 |
[1] RRM1 |
[5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
[11] 28, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285 |
29 |
Glucocorticoids |
- |
- |
- |
- |
[6] 40, 41, 43, 44, 60, 62 |
30 |
Human monoclonal antibody directed against complement 5 protein |
- |
- |
- |
- |
[1] 62 |
31 |
Iron |
Iron |
- |
- |
- |
[7] 13, 62, 86, 96, 97, 254, 284 |
32 |
Iron dextran |
Iron dextran |
D02141 |
- |
- |
[1] 62 |
33 |
Iron sucrose |
Sucrose |
D00025 |
- |
- |
[3] 62, 96, 97 |
34 |
Levamisole |
Levamisole |
D00750, D08114 |
- |
- |
[3] 60, 61, 62 |
35 |
Levamisole+cyclosporin a+glucocorticoids |
Levamisole |
D00750, D08114 |
- |
- |
[2] 60, 62 |
36 |
Lfg316 |
- |
- |
- |
- |
[1] 62 |
37 |
Lnp023 |
- |
- |
- |
- |
[3] 62, 66, 222 |
38 |
Melphalan |
Melphalan |
D00369 |
- |
- |
[14] 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285 |
39 |
Methotrexate |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[33] 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
40 |
Mycophenolate |
Mycophenolic acid |
D05096 |
[2] IMPDH1, IMPDH2 |
[3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
[33] 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
41 |
Mycophenolate mofetil |
Mycophenolate mofetil |
D00752, D05094, D05095 |
[2] IMPDH1, IMPDH2 |
[3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
[32] 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
42 |
Myeloablative preparative regimen |
- |
- |
- |
- |
[3] 62, 65, 284 |
43 |
Phosphate |
Phosphate ion |
- |
- |
- |
[29] 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
44 |
Ra101495 |
- |
- |
- |
- |
[1] 62 |
45 |
Ra101495 sodium |
- |
- |
- |
- |
[1] 62 |
46 |
Ravulizumab |
Ravulizumab |
D11054 |
[1] C5 |
[7] Complement and coagulation cascades, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Pertussis, Prion diseases, Staphylococcus aureus infection, Systemic lupus erythematosus |
[3] 11, 62, 109 |
47 |
Reduced intensity preparative regimen |
- |
- |
- |
- |
[3] 62, 65, 284 |
48 |
Reduced toxicity ablative regimen |
- |
- |
- |
- |
[3] 62, 65, 284 |
49 |
Regn3918 |
- |
- |
- |
- |
[1] 62 |
50 |
Ro7112689 |
- |
- |
- |
- |
[1] 62 |
51 |
Ro7112689/f01 |
- |
- |
- |
- |
[1] 62 |
52 |
Rva576 |
- |
- |
- |
- |
[3] 62, 109, 162 |
53 |
Rva576 (coversin) |
Nomacopan |
D11473 |
[1] C5 |
[7] Complement and coagulation cascades, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Pertussis, Prion diseases, Staphylococcus aureus infection, Systemic lupus erythematosus |
[2] 62, 109 |
54 |
Sargramostim |
Sargramostim |
D05803 |
[1] CSF2RA |
[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
[6] 6, 28, 60, 62, 96, 229 |
55 |
Sb12 (proposed eculizumab biosimilar) |
Eculizumab |
D03940 |
[1] C5 |
[7] Complement and coagulation cascades, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Pertussis, Prion diseases, Staphylococcus aureus infection, Systemic lupus erythematosus |
[1] 62 |
56 |
Sirolimus |
Sirolimus |
D00753 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[30] 13, 17, 34, 35, 36, 46, 51, 60, 62, 63, 65, 66, 67, 85, 89, 96, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 |
57 |
Soliris |
Eculizumab |
D03940 |
[1] C5 |
[7] Complement and coagulation cascades, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Pertussis, Prion diseases, Staphylococcus aureus infection, Systemic lupus erythematosus |
[7] 11, 13, 14, 62, 109, 222, 223 |
58 |
Soliris (eculizumab) |
Eculizumab |
D03940 |
[1] C5 |
[7] Complement and coagulation cascades, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Pertussis, Prion diseases, Staphylococcus aureus infection, Systemic lupus erythematosus |
[1] 62 |
59 |
Sterile normal saline (0.9% nacl) |
- |
- |
- |
- |
[3] 62, 234, 254 |
60 |
Study drug - alxn1210 |
- |
- |
- |
- |
[1] 62 |
61 |
Sucrose |
Sucrose |
D00025 |
- |
- |
[3] 62, 96, 97 |
62 |
Synthetic 15-amino-acid macrocyclic peptide |
- |
- |
- |
- |
[1] 62 |
63 |
Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol24 palmitoylated linker |
- |
- |
- |
- |
[1] 62 |
64 |
Systematic chemotherapy and antibodies |
- |
- |
- |
- |
[1] 62 |
65 |
Systemic chemotherapy and antibodies |
- |
- |
- |
- |
[2] 62, 326 |
66 |
Tacrolimus |
Tacrolimus |
D00107, D08556 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[29] 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
67 |
Zilucoplan (ra101495) |
- |
- |
- |
- |
[2] 11, 62 |
68 |
lnp023 hydrochloride salt |
- |
- |
- |
- |
[2] 62, 66 |